What do systematic reviews say?

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

The review found no eligible studies for this question.

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: monoclonal antibody KB001‐A vs placebo

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  RR 0.25 [0.03, 2.4]
  2 studies · 196 participants
  Low

Summary of findings: nitric oxide vs placebo

The review found no eligible studies for this question.

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: garlic supplementation vs placebo

The review found no eligible studies for this question.

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ECM vs ECT

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ECM vs ECMM

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ECM vs a different ECM

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ECM vs TPE

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ECM vs other enteric‐coated preparations

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: low‐dose vs high‐dose PERT

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ECM vs NECT plus cimetidine

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs PEP mask therapy

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 253 participants
  Moderate

Summary of findings: β‐carotene vs placebo

Summary of findings: β‐carotene showed no clear difference in pulmonary exacerbations Days of antibiotic use compared with placebo (low certainty).

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Low

Summary of findings: β‐carotene vs placebo

The review found no eligible studies for this question.

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: liprotamase vs porcine PERT

Summary of findings: liprotamase showed no clear difference in pulmonary exacerbations: number of exacerbations compared with porcine PERT (low certainty).

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  OR 0.56 [0.13, 2.45]
  1 study · 128 participants
  Low

Standard rhGH vs no treatment

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 94 participants
  Very low

High‐dose rhGH vs placebo

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with placebo (low certainty).

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  RR 1.92 [0.66, 5.61]
  1 study · 42 participants
  Low

High‐dose rhGH vs standard‐dose rhGH

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with standard‐dose rhGH (low certainty).

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  RR 1.28 [0.52, 3.18]
  1 study · 42 participants
  Low

Standard rhGH vs placebo

Standard rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with placebo (low certainty).

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  RR 1.5 [0.49, 4.59]
  1 study · 44 participants
  Low